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Abstract
Background: Important insight into the mechanisms through which gene-environmental interactions cause
schizophrenia can be achieved through preclinical studies combining prenatal immune stimuli with disease-related
genetic risk modifications. Accumulating evidence associates JNK signalling molecules, including MKK7/MAP2K7,
with genetic risk. We tested the hypothesis that Map2k7 gene haploinsufficiency in mice would alter the prenatal
immune response to the viral mimetic polyriboinosinic-polyribocytidylic acid (polyI:C), specifically investigating the
impact of maternal versus foetal genetic variants.
Methods: PolyI:C was administered to dams (E12.5), and cytokine/chemokine levels were measured 6 h later, in
maternal plasma, placenta and embryonic brain.
Results: PolyI:C dramatically elevated maternal plasma levels of most cytokines/chemokines. Induction of IL-1β, IL-2,
IL-10, IL-12, TNF-α and CXCL3 was enhanced, while CCL5 was suppressed, in Map2k7 hemizygous (Hz) dams relative
to controls. Maternal polyI:C administration also increased embryonic brain chemokines, influenced by both
maternal and embryonic genotype: CCL5 and CXCL10 levels were higher in embryonic brains from Map2k7 dams
versus control dams; for CCL5, this was more pronounced in Map2k7 Hz embryos. Placental CXCL10 and CXCL12
levels were also elevated by polyI:C, the former enhanced and the latter suppressed, in placentae from maternal
Map2k7 Hzs relative to control dams receiving polyI:C.
Conclusions: The results demonstrate JNK signalling as a mediator of MIA effects on the foetus. Since both
elevated CXCL10 and supressed CXCL12 compromise developing GABAergic interneurons, the results support
maternal immune challenge contributing to schizophrenia-associated neurodevelopmental abnormalities. The
influence of Map2k7 on cytokine/chemokine induction converges the genetic and environmental aspects of
schizophrenia, and the overt influence of maternal genotype offers an intriguing new insight into modulation of
embryonic neurodevelopment by genetic risk.
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Background
Schizophrenia, which affects around 1% of the popula-
tion, is caused by the combined action of genetic and
environmental risk factors. In recent years, there has
been considerable progress in understanding the genetic
contribution to disease risk. For most patients, this de-
rives from the interaction of a large number of common
genetic variants, all individually contributing a small in-
crease in risk [1]. In other patients, rare variants have a
proportionately larger effect. Many of the variants associ-
ated with schizophrenia, both common and rare, can be
functionally aligned with glutamatergic signalling mecha-
nisms [2–5]. The proteins involved encompass structural
molecules of the post-synaptic specialisation (such as Arc
and PSD95) and downstream signalling molecules.
There is a substantial body of research indicating that
environmental risk factors that act during the pre-, peri-
and early postnatal period are also important in the
pathogenesis of schizophrenia in adult offspring [6, 7].
Stressful events, such as psychological trauma, maternal
malnutrition, gestational infection and other obstetric
complications, cause physiological changes in the devel-
oping foetal environment, disturbing the normal course
of brain development and inducing structural and func-
tional brain abnormalities which emerge later, in adult
life [6–8]. In particular, maternal infection and the asso-
ciated inflammatory response in the mother (and pos-
sibly in the developing foetal brain) have been a
significant focus of investigation. The effect of maternal
immune activation (MIA) on offspring in preclinical ro-
dent models (reviewed in [9]) continues to provide
insight into the potential pathogenic mechanisms in-
volved in prenatal infection and the neurodevelopmental
hypothesis of schizophrenia [10].
MIA using polyriboinosinic-polyribocytidylic acid (polyI:C),
a double-stranded RNA virus mimetic, is a particularly
well-studied method of immune activation [11–13]. PolyI:C
is recognised by toll-like receptor 3 (TLR3) [14], and a strong
inflammatory response is initiated that brings cells to the site
of infection in order to help kill the invading pathogen. This
occurs via the activation of kinase signalling cascades, most
prominently the JNK and NF-κB pathways [15, 16], subse-
quently upregulating genes coding for pro- and anti-inflam-
matory mediators such as cytokines, chemokines and
colony-stimulating factors (CSFs) [17, 18].
PolyI:C administration to gestating rodents has repeat-
edly been shown to induce molecular, structural, physio-
logical and behavioural changes related to schizophrenia
in adult offspring [12, 13]. Reported molecular changes
in the offspring include altered microglial staining, al-
tered dopamine metabolism in the striatum, alterations
in glutamic acid decarboxylase-67 (GAD-67) expression
and reduced parvalbumin expression in the prefrontal
cortex [19–21].
These findings have provided a new impetus to attempts
to identify rodent models of aspects of schizophrenia
neurobiology with improved construct validity—the com-
bination of genetic risk factors with developmental im-
mune challenge. Of the few studies so far reported,
mutations in the DISC1 gene have been combined with
prenatal [22] or early postnatal [23] administration of
polyI:C. Another group [24] combined mice with a hemi-
zygous functional deletion of the neuregulin (Nrg1) gene
with maternal polyI:C exposure. However, the genetic var-
iants studied in this respect to date have no obvious rela-
tionship with the environmental stimulus. The recent
evidence implicating the JNK signalling pathway, and spe-
cifically the kinases involved in JNK activation, such as
MKK7 (MAP2K7) [25], ULK4 [26], and VRK2 and
TAOK2 [4, 27], in genetic risk for schizophrenia [2, 28] is
of particular interest, since MKK7-JNK signalling is not
only involved in glutamatergic signalling in the CNS [29],
but is also believed to mediate aspects of the innate im-
mune response [30]. The potential link between genetic
risk and environmental risk is clearly intriguing.
Mice hemizygous for a functional deletion of the
Map2k7 gene (Map2k7 Hz mice) show reduced CNS ex-
pression of MKK7, along with subtle cognitive deficits
characteristic of patients with schizophrenia, including
an inability to sustain attention in cognitive tasks [31].
This study tests the hypothesis that Map2k7 Hz mice
also show an altered cytokine/chemokine response to
maternal immune challenge. Gestating dams at E12.5
are exposed to polyI:C and the immune response profile
determined in maternal plasma and brains of the devel-
oping embryos.
Methods
Maternal immune activation
Mice hemizygous for a functional deletion of the Map2k7
gene (Map2k7 Hz mice) [32], and wild-type (WT) C57Bl6
mice (littermates with Map2k7 Hz mice), were used in the
experiment. Mice were time mated according to the combi-
nations outlined in Table 1. Mouse pairs were put together
at 5 p.m. and separated in the morning the next day. If they
had conceived, this was taken as embryonic day 0.5. Female
mice were weighed and monitored for 12 days.
Female mice weighed 22.1 ± 0.34 g on average at the
start of the experiment and 28.7 ± 0.77 g on average
when 12.5 days pregnant. All mice were aged 12.23 ±
0.47 weeks at the point of conception. Mice were singu-
larly housed (when not paired) in a temperature and hu-
midity controlled room with a 12-h light/dark cycle
(lights on at 07:00) in accordance with the Animals
(Scientific Procedures) Act 1986. Pregnant dams were
weighed and given either 20 mg/kg at 2 ml/kg polyI:C or
2 ml/kg saline on embryonic day 12.5. This dose has pre-
viously been shown to induce long-lasting behavioural
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and pharmacological changes in mouse offspring [33]
and is arguably the optimal dose that causes MIA [34].
With respect to brain development [35] and brain gene
expression [36], it has been argued that embryonic day
12.5 may be equivalent to approximately the 54th day
(7.8th week) of gestation for humans. Therefore, embry-
onic day 12.5 is the murine equivalent of three quarters
of the way through trimester 1 in humans, a period
where the developing nervous system is particularly vul-
nerable to maternal infection and most associated with
increased incidence of schizophrenia [37]. All injections
were given subcutaneously to avoid accidental injection
into an embryo.
Protein extraction for ELISA and Luminex
Six hours following the polyI:C or saline injection, the
pregnant dam was injected with a lethal dose (0.1 ml) of
pentobarbital sodium (Euthatal, Merial Animal Health
Ltd.) and trunk blood was collected via cardiac puncture
into an EDTA-coated syringe. The blood was injected
into an EDTA-coated 1.5-ml Eppendorf tube containing
an additional 80 μl EDTA and shaken. Following centri-
fugation at 10,000g at 4 °C for 10 min, the supernatant
(plasma) was frozen at − 80 °C until ELISA or Luminex
assay were conducted.
The placentae and embryos were carefully re-
moved, and the brain, placentae and a small amount
of tissue (for genotyping) kept at − 80 °C until re-
quired. Within each litter, embryonic brain samples
were pooled for genotype after genotyping, so that
each litter yielded one WT and one Map2k7 Hz
pooled brain extract. The brain tissue was homoge-
nised manually in 275 μl lysis buffer (1x PBS with
0.1% Triton X-100 (Sigma), 5 μM EDTA (GIBCO)
and proteinase inhibitors (Sigma)) and then centri-
fuged at 8000g for 10 min at 4 °C. The supernatant
containing the protein was then halved (~ 110 μl
each): one for ELISA and one for Luminex. Embry-
onic brain protein concentrations were determined
by bicinchoninic acid (BCA) assay (Merck) according
to the manufacturer’s instructions.
Luminex assay
The concentration of 20 cytokines, chemokines and
colony-stimulating factors were determined simultan-
eously in maternal plasma and embryonic brain tissue
supernatant using a mouse cytokine magnetic 20-plex
assay according to the manufacturer’s instructions (Invi-
trogen: LMC0006M). Samples were analysed in dupli-
cate: the coefficient of variation (% CV) was checked; a
plate was considered acceptable if the mean CV < 15%
and if not more than 20% of duplicates have CV > 25%.
The mean CV for each plate was 5.25% and 6.74%, and
the percentage of duplicates which have a CV > 25% was
1.35% and 3.12% for each plate, respectively, which was
well within this range. Further details are provided in
Additional file 1. Embryonic brain concentrations were
normalised to total protein via the BCA assay.
ELISA
Since CCL5 is a relatively well-characterised component
of the innate immune response, but is not represented
on the Luminex assay employed for the other cytokines/
chemokines, CCL5 levels in maternal plasma and em-
bryonic brain tissue supernatant were measured by
enzyme-linked immunosorbent assay (ELISA). Add-
itional measurements of CXCL10 and CXCL12 levels in
placenta were also performed by ELISA. Mouse Quanti-
kine® ELISAs, MMR00, MCX100 and MCX120 (R&D
Systems, Abingdon, UK), were utilised according to the
manufacturer’s instructions. Fifty microlitre of assay dilu-
ent (provided) and 50 μl of the diluted standards and
samples (undiluted) were assayed in duplicate. The op-
tical density was then read by a plate reader (Multiskan
Spectrum, Thermo Fisher). Embryonic brain and pla-
centa concentrations were normalised to total protein as
established by the BCA assay.
Low level processing and statistical analysis
For the maternal plasma measurements, 14 of the 21 im-
mune response/growth factor molecules analysed were
within a detectable range and met criteria for inclusion
in analyses (see Additional file 1); for the embryonic
brain measurements, five were detectable. This is most
Table 1 Mating combinations. Four pairs in each group were successfully time mated, totalling 16 pairs. Each pair produces WT and
Map2k7 Hz embryos
Breeding Treatment Maternal plasma samples Litters Independent WT
embryonic brain samples
Independent Hz
embryonic brain samples
Female WT ×
Male Map2k7 Hz
Saline (vehicle) 4 × WT 4 4 4
Female WT ×
Male Map2k7 Hz
PolyI:C
(20 mg/kg sc.)
4 × WT 4 4 4
Female Map2k7 Hz × Male WT Saline (vehicle) 4 × Hz 4 4 4
Female Map2k7 Hz × Male WT PolyI:C
(20 mg/kg sc.)
4 × Hz 4 4 4
Openshaw et al. Journal of Neuroinflammation           (2019) 16:18 Page 3 of 11
likely because the levels of immune molecules are sub-
stantially lower in embryonic brain tissue than in maternal
blood plasma [34] and/or not present in embryonic brain
at detectable levels at this stage of development [17].
All statistical analyses were carried out using Minitab 17
Statistical Software. For maternal plasma, each cytokine
was analysed separately by a two-way ANOVA with ma-
ternal genotype (WT or Map2k7 Hz) and drug (saline or
polyI:C) as between-subjects factors. For embryonic brain,
each cytokine was analysed separately by a three-way
ANOVA with maternal genotype (WT or Map2k7 Hz),
embryonic genotype (WT orMap2k7 Hz) and drug (saline
or polyI:C) as between-subjects factor and each litter
nested within maternal genotype and drug. Two-way pair-
wise comparisons were made between factors using
Tukey’s method. Data are presented as mean ± standard
error of the mean (SEM), and results were considered sig-
nificant if p < 0.05. Some of the cytokine levels measured
returned zero values, because of levels below detection
only in saline groups. Therefore, some data groups did not
show equal variances and normal distribution. However,
data within polyI:C treatment groups alone showed nor-
mal distributions. Where significant departure from nor-
mality was detected, a box-cox transformation of the data
was employed. Where substantial departure from Gauss-
ian distribution was noted, ANOVAs were performed only
on the polyI:C groups, or by non-parametric analysis, for
additional confirmation.
Results
Maternal plasma from mice injected with polyI:C had in-
creased levels of most immune molecules detected com-
pared to those injected with saline. Of the 12 cytokines/
chemokines tested that were detectable in maternal
plasma, all were elevated following polyI:C administra-
tion compared to saline: IL-1β, IL-2, IL-5, IL-6, IL-10,
IL-12, TNF-α, CCL2, CCL5, CXCL1, CXCL9 and
CXCL10 (Fig. 1). Interestingly, the levels of IL-2, IL-6,
IL-10, TNF-α and CXCL1 were significantly higher in
plasma from Map2k7 Hz mice compared to WT con-
trols overall, independent of treatment. Furthermore, the
levels of IL-2, IL-10, IL-12, TNF-α and CXCL1 were sig-
nificantly higher in plasma from Map2k7 Hz mice com-
pared to WT controls after polyI:C treatment.
Conversely, the levels of CCL5 were significantly lower
in plasma from Map2k7 Hz mice after polyI:C treatment
(Fig. 1).
CCL5 and CXCL10 were elevated in embryonic brain
following polyI:C
None of the cytokines tested were found to be above the
threshold for detection in embryonic brain. Of the che-
mokines analysed, three were within a detectable range
and met criteria for inclusion in analyses: CCL2, CCL5
and CXCL10. Interestingly, under basal conditions, the
levels of CXCL10 in embryonic brain were higher with
Map2k7 Hz mothers than with WT mothers (p < 0.01)
(Fig. 2c). Equally, embryos from Map2k7 Hz dams had
increased CCL5 brain levels overall compared to em-
bryos from WT dams (p = 0.031) (Fig. 2b), illustrating
the operation of maternal genotype effects on foetal
brain chemokine expression.
Analysis suggested that, overall, CCL2 was not ele-
vated in embryonic brain in response to maternal
polyI:C exposure (Fig. 2a). However, CCL5 and CXCL10
levels were significantly increased in the brains of em-
bryos whose mother had been exposed to polyI:C com-
pared to the brains of embryos whose mother had been
given saline (Fig. 2b, c). In addition, after polyI:C adminis-
tration, Map2k7 Hz embryos from Map2k7 Hz mothers
had a greater induction of brain CCL5 levels compared to
Map2k7 Hz embryos from WT mothers (Fig. 2b).
When within-litter differences due to foetal genotype
were compared directly, by subtracting the level in the
pooled WT foetal brains from the level in the pooled
Map2k7 Hz foetal brains, for each litter, the data sug-
gested that, following maternal polyI:C exposure, there
was an interaction between maternal and foetal geno-
type, resulting in a relatively greater induction of foetal
brain CCL2 and CXCL10, in Map2k7 Hz offspring from
Map2k7 Hz dams (Fig. 3).
The growth factor basic FGF was not elevated follow-
ing polyI:C administration, either in maternal plasma
(Fig. 4b) or in embryonic brain (Fig. 4d). VEGF levels
were raised in Map2k7 Hz dam plasma relative to WT
controls (Fig. 4a), but were not significantly affected in
embryonic brain (Fig. 4c).
As the main barrier to immune communication be-
tween factors in the maternal blood and in the foetus,
the placenta is potentially important in the effect of ma-
ternal immune activation on the foetal brain. Indeed,
preeclampsia is one of the clearest risk factors for future
development of schizophrenia in offspring [37, 38]. We
therefore additionally monitored the expression of two
key mediators in the placenta from these mice: CXCL10
(originally IP-10) and CXCL12 (originally SDF-1) are
both implicated in preeclampsia and in the innate im-
mune response to Toxoplasma gondii [39–43]. In
addition, increased CXCL10 [44] and decreased CXCL12
have been linked to impaired migration and function of
cortical GABAergic interneurons [45, 46] and so may
have particular relevance to schizophrenia risk.
We found that there was a clear interaction of the ef-
fect of polyI:C with maternal genotype, such that, after
the immune challenge, placental CXCL10 was elevated
to a greater extent in Map2k7 Hz dam placentae. In
contrast, CXCL12 levels were elevated by polyI:C admin-
istration only in placentae from WT, but not in Map2k7
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HZ dams. There was no significant influence of the em-
bryonic genotype (Fig. 5). Interestingly, there was also no
detectable correlation between placental and embryonic
brain levels of CXCL10 (in Additional file 1: Figure S1).
Discussion
The results obtained in this study reveal that the immune
response of Map2k7 Hz mice differs from that of control
mice, following maternal exposure to the viral mimetic
polyI:C. This implicates JNK signalling in aspects of MIA.
We confirm previous reports that MIA using polyI:C trig-
gers an immune response in the foetal brain. We also
present evidence that the levels of immune mediators in
the foetal brain are affected by the maternal genotype as
well as the embryonic genotype.
Maternal plasma cytokine/chemokine response
MIA with polyI:C in gestating rodents is a popular ex-
perimental paradigm [11, 47]. However, the profile of
the immune response to polyI:C in the maternal plasma
Fig. 1 Cytokine levels in maternal plasma as measured by Luminex multiplex panel or ELISA (CCL5 only). All detectable cytokines/chemokines
were elevated in the plasma of mothers that received polyI:C compared to those that received saline. Plasma IL-2, IL-10, IL-12, TNF-α and CXCL1
were significantly more elevated in Map2k7 Hz mice than they were in WT mice, following polyI:C administration compared to saline. Results
shown are mean ± SEM, N = 4/group. Data were analysed by two-way ANOVA with maternal genotype (WT or Map2k7 Hz) and treatment (saline
or polyI:C) as factors. F values are provided in Additional file 1. *p < 0.05, **p < 0.01, ***p < 0.001 (main effect—ANOVA). #p < 0.05 vs WT, the same
treatment (post-hoc Fisher’s test)
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has seldom been documented. Meyer et al. [20] reported
increased levels of IL-1β, IL-6, IL-10 and TNF-α in ma-
ternal plasma 6 h after polyI:C administration in mice at
E9 or E16. One other study assessed a relatively full pro-
file of the immune response and reported that the same
dose of polyI:C (20 mg/kg) to that used here increased
levels of IL-6, IL-10, IL-12, IL-13, IL-15, TNF-α, IFN-γ,
CCL2, CCL3, CCL5, CXCL1, CXCL9, CXCL10, VEGF
and GM-CSF in maternal serum 6 h following exposure
at E16 [17]. Our findings in maternal plasma correspond
to those of Arrode-Brusés and Brusés [17] for the major-
ity of immune molecules (increased levels of IL-6, IL-10,
IL-12 and TNF-α, CCL2, CCL5, CXCL1, CXCL9,
CXCL10). We also found an increase in IL-1β, IL-5 and
IL-2, which they did not assay, and we did not observe
their reported increase in VEGF. Overall, however, our
findings are closely matched and show that the levels of
a broad spectrum of immune molecules are increased
following administration of a viral mimetic. The minor
differences may be a result of the differences in foetal
age [20], as there are fluctuations in the functioning of
the maternal host’s immune system as pregnancy pro-
gresses [48]. It is also worth noting that many of the cy-
tokines altered in the maternal serum are also elevated
in the blood of patients with schizophrenia, including
IL-1β, IL-2, IL-6, IL-12 and TNF-α [49–53].
Differential upregulation of maternal plasma cytokines/
chemokines in Map2k7 Hz and WT mice
Twelve cytokines/chemokines were increased in mater-
nal plasma following polyI:C exposure. Of these, IL-2,
IL-10, IL-12, TNF-α and CXCL1 were all increased to a
Fig. 2 Chemokine levels in embryonic brain as measured by Luminex Multiplex panel or ELISA (CCL5 only). CCL2 levels were unaffected by genotype
or treatment (a). Overall, CCL5 (b) and CXCL10 (c) levels were significantly increased in the brains of embryos whose mother had been exposed to
polyI:C, compared to brain levels in embryos whose mother had received saline. Results shown are mean ± SEM. Data analysed by three-way ANOVA
with embryonic genotype, maternal genotype, and treatment as factors. F values are provided in Additional file 1. N = 4/group. ***p < 0.001 effect of
treatment (ANOVA); ##p < 0.01 as shown; *p < 0.05, **p < 0.01 vs WT dam, the same treatment and embryo genotype (post-hoc Fisher’s test)
Fig. 3 Within-litter differences for chemokine levels in embryonic brain as measured by Luminex Multiplex panel or ELISA (CCL5 only). Overall,
CCL2 (a) and CXCL10 (c) brain differences between embryo genotypes were significantly altered after polyI:C in Hz dams—*p = 0.04
(CCL2) or p = 0.03 (CXCL10)—vs WT dams, same treatment (Mann-Whitney test). Results shown are mean ± SEM, N = 4/group
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significantly greater extent in maternal plasma of Map2k7
Hz mice compared to WT mice. In contrast, the elevation
of CCL5 was suppressed in Map2k7 Hz mice. Our results
imply that maternal MKK7-JNK signalling acts to pro-
mote CCL5 induction and dampen the activation of IL-2,
IL-10, IL-12, TNF-α and CXCL1.
Traditionally, JNK signalling is linked to positive tran-
scriptional effects on immune response genes [54]. The ele-
vated response for many factors due to haploinsufficiency
for Map2k7 is therefore at first sight surprising. However,
JNK activation suppresses IL-2, IL-4 and IL-10 production
in T cells [55], an effect mediated by MKK7. Hence, an
Fig. 4 Growth factor levels in a, b maternal plasma, and c, d embryonic brain. VEGF levels (a, c) and basic FGF levels (b, d) were not significantly
affected, in either maternal plasma or brain, by polyI:C administration. Results shown are mean ± SEM, *p < 0.05 (ANOVA); #p < 0.05 vs WT dams,
same treatment (post-hoc Fisher’s test); F values are provided in the Additional file 1. N = 4/group
Fig. 5 CXCL10 and CXCL12 levels in placenta. CXCL10 levels in placental tissue, measured by ELISA, were increased by polyI:C administration in
placentae from Map2k7 Hz dams but not WT dams, irrespective of the embryonic genotype (a). Conversely, CXCL12 levels were increased by
polyI:C administration in placentae from WT dams but not Map2k7 Hz dams in placental tissue, again irrespective of the embryonic genotype (b).
Results shown are mean ± SEM, N = 4–7/group. #p < 0.05, ##p < 0.01 as shown, *p < 0.05, **p < 0.01 vs vehicle-treated group, same dam and
embryo genotype (post-hoc Fisher’s test); F values are provided in the Additional file 1
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enhanced response for IL-2 and IL-10 to polyI:C could be
predicted. It may be that positive transcriptional responses
to immune challenge are mediated predominantly via
MKK4 (which can activate both JNKs and p38s) rather than
MKK7 (which is specific for MKK7) [56]. Since MKK7 and
MKK4 are seldom studied selectively, it could be very intri-
guing to follow-up this prediction. Consistent with this
idea, we note that inhibition of MKK7 mRNA splicing re-
sults in an elevated TNF-α response in T cells [57].
Increased inflammation in itself may not cause damage to
the CNS, so long as the levels of anti- and pro-inflammatory
cytokines and chemokines are regulated in a co-ordinated
manner. Unbalanced upregulation of either anti- or pro-in-
flammatory cytokines may disrupt the intricate balance usu-
ally maintained throughout normal neurodevelopment. Of
the immune molecules differentially regulated inMap2k7 Hz
mice compared to WTs, one is anti-inflammatory (IL-10)
and three are pro-inflammatory (TNF-α, IL-2 and IL-12).
IL-6 is considered both anti- and pro-inflammatory. There-
fore, it is conceivable for there to be an imbalance of pro- vs.
anti-inflammatory cytokines in Map2k7 Hz mice that have
been exposed to viral infection. Overall, these results suggest
that gestating Map2k7 Hz mice have a less well-controlled/
regulated immune response to viral infection.
The elevation in VEGF levels is of interest. Patients
with schizophrenia have been reported to have higher
plasma VEGF levels than controls [58] and lower brain
(prefrontal cortex) levels [59]. Suppressed JNK signalling
has generally been associated with negative effects on
VEGF expression [60], so the elevated plasma levels in
Map2k7 Hz mice may be secondary to increased cyto-
kine levels (for example IL-6 [61]).
Embryonic brain
In embryonic brain, Meyer et al. [20] reported elevated
levels of IL-1β, IL-6 and IL-10 at 3 or 6 h, which were to
some extent dependent on the gestational day of polyI:C
administration. Increased brain levels of IL-1β and IL-5,
but not IL-6 or IL-10, were also reported 6 h after polyI:C
at E9 [22]. Another investigation found IL-1β, CCL2,
CXCL9, CXCL10 and VEGF to be increased in embryonic
brain following maternal exposure to polyI:C at E16 [17].
Of the cytokines that were in a detectable range in the
embryonic brain, we found an overall increase only in
CXCL10 and CCL5 but not in VEGF in response to
polyI:C exposure. Other studies that used 20mg/kg
polyI:C could either not detect CCL5 or it was not con-
tained within the set of cytokines that they measured.
Interestingly, in the current study, CCL2 was increased
following polyI:C in maternal plasma and was detectable
in embryonic brain but did not show an overall increase
following maternal polyI:C, in contrast to Arrode-Bruses
and Bruses (2012), who found CCL2 to be increased in
foetal brain 6 h following PolyI:C exposure.
Maternal haploinsufficiency for Map2k7 resulted in ele-
vated basal CXCL10 levels in embryonic brain. This is
consistent with evidence that JNK suppresses polyI:C-sti-
mulated activation of CXCL10 in macrophages [62]. Em-
bryonic brain from Map2k7 Hz mothers also showed an
increased CCL5 induction in response to polyI:C. This is
in clear contrast to the lower CCL5 induction in plasma
from Map2k7 Hz mothers and emphasises the complexity
of genetic effects on the innate immune response.
It could be proposed that paternal genotype, as well as
maternal genotype, might influence the embryonic brain
response to MIA. There is a literature on increased risk
of schizophrenia with advancing paternal age, which has
been interpreted to suggest an inheritance of paternal
genetic or epigenetic risk factors, via mechanisms such
as paternal imprinting [63, 64]. However, it has now be-
come clear that, for schizophrenia, this is not in fact a
paternally derived genetic or epigenetic risk, but rather
an epiphenomenon, possibly linked to corresponding in-
creases in maternal age [65]. Therefore, we consider it is
safe to assume that it is the maternal genotype which is
the pre-eminent factor at work.
Embryonic haploinsufficiency for Map2k7 resulted in
increased brain CCL5 production, and an elevated CCL2
and CXCL10 response, to polyI:C. While there are few
previous studies of the role of JNK on chemokine re-
sponses of immune cells, to place these results in con-
text, those available would have predicted a general
reduction in CCL5 production due to haploinsufficiency
for Map2k7. JNK inhibition (albeit using potentially
non-selective pharmacological tools) reportedly dampens
chemokine (CCL2/CCL5) production as a result of
polyI:C exposure in T cells [66], and in microglial cells,
JNK inhibition reduces polyI:C-stimulated induction of
CCL5, but not CXCL10 [67]. The data reported here
strongly implicate JNK signalling in the embryonic brain
chemokine response to maternal infection and reveal a
complex interplay between maternal and embryonic
genotypes.
Altered peripheral CCL5 levels have been detected in
patients with schizophrenia [68, 69], which is of interest
considering the data presented here, and the genetic
association between schizophrenia and JNK pathway
genes. The role of CCL5 in the CNS is not well-charac-
terised. It is thought to be produced by neurons, oligo-
dendrocytes, astrocytes and microglia [70], and, apart
from a role in neuroinflammation, evidence that CCL5
can modulate synaptic glutamate release [71] may be
particularly relevant to schizophrenia risk. Patients with
schizophrenia, and those at high risk of developing the
disease, show abnormal cortical glutamate levels [72].
While various mechanisms may be involved, the dysreg-
ulation of brain chemokines is likely to produce
long-term effects on CNS development.
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Placenta
The placental environment will be important in foetal
chemokine production as a result of MIA. This is rein-
forced by the increased schizophrenia risk associated with
preeclampsia [38]. It has been noted experimentally that
placenta-specific deletion of IL-6 prevents MIA-induced
elevation in CXCL10 of foetal brain and reduces foetal
brain VEGF and bFGF levels [73], emphasising the im-
portance of the placenta for communicating the effects of
maternal infection to the foetus.
CXCL10 expression was enhanced in the placenta
from Map2k7 Hz mice relative to controls. This is simi-
lar to the observations in embryonic brain and reinforces
the evidence that MKK7-JNK signalling negatively regu-
lates the expression of this chemokine. CXCL10 is a key
mediator in preeclampsia [40, 74] and in the innate im-
mune response to Toxoplasma Gondii [39], two of the
best established immune risk factors for schizophrenia
[6, 37, 38], so this has implications for understanding
gene × environment risk interactions in the disease.
CXCL10 has a suppressive effect on developing GABAergic
interneurons, reducing GAD65/67 expression [44], so in-
creased CXCL10 levels are likely have a detrimental effect
on this population of cells. Note that CXCL10 can also affect
synaptic glutamate responses [44], so CXCL10 dysregulation
may potentially exacerbate any latent dysfunction of gluta-
matergic transmission in subjects with genetic risk for
schizophrenia. CXCL12 is another chemokine strongly
linked to preeclampsia and the placental trophoblast re-
sponse to infection [41, 75, 76]. In contrast to the situation
with CXCL10, the placenta CXCL12 response to polyI:C
was suppressed in Map2k7 Hz mice. It is known that de-
creased CXCL12 impairs migration and developmental
function of cortical GABAergic interneurons [45, 46], so a
reduction in CXCL12 is likely to compound the negative ef-
fects of increased CXCL10 on these cells.
Maternal effects
In GWAS studies of schizophrenia, the genetic variants
detected, comparing patients with control subjects, ex-
plain only a small proportion of the genetic risk associ-
ated with the disease—the remainder is the so-called
missing heritability. Any influence, on offspring disease
risk, of maternal genetic risk factors, acting for example via
the inter-uterine environment, manifests in case-control as-
sociation studies as an offspring genotype effect at reduced
penetrance [77–79]. There is increasing awareness that
such maternal effects should be considered when interpret-
ing GWAS data. In phenotypes obviously dependent on
both offspring and maternal factors, where maternal and
offspring single-nucleotide polymorphisms (SNPs) are com-
pared for their influence on offspring phenotype, the mater-
nal SNPs can show the greater effect size (e.g. [80]). Hence,
there is the possibility that some of the missing heritability
in psychiatric disease derives from the effect of maternal
genetic risk factors influencing the uterine environment,
during prenatal exposure to environmental risk factors. Re-
cent evidence supports this proposal in the case of autism
spectrum disorders [81], where of course there is also a
strong link to MIA. Indeed, there is some evidence suggest-
ing that risk of schizophrenia in offspring may be increased
to a greater extent by maternal genotype as compared to
paternal genotype [82]. Our data are consistent with this,
currently under-considered, hypothesis. They show that an
interaction between environmental factors and maternal
genotype influences the exposure of the developing embryo
to chemokines known to influence GABA interneurone de-
velopment. Future studies can test whether maternal geno-
type operates in a similar fashion in clinical populations.
Conclusions
Our results clearly reveal that MKK7-JNK signalling
plays a role in the viral immune response and that dis-
ruption of MKK7-JNK signalling affects both maternal
and foetal induction of cytokines and chemokines. This
disruption can be detected at various levels of the mater-
nal and foetal response—in the maternal plasma, in the
placenta and in embryonic brain. While illuminating the
complexity of the interaction of genetic factors with
the immune response in MIA, our results may be es-
pecially important in revealing the currently under-
emphasised influence of maternal genotype on the
foetal response to MIA.
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